Meningioma
Conditions
Brief summary
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Interventions
DIAGNOSTIC_TESTDOTATATE-PET scan
DOTATATE tracer PET scan for meningioma
Sponsors
British Columbia Cancer Agency
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Able and willing to comply with the study procedures * Intact meningioma requiring definitive radiation * Post-operative meningioma requiring adjuvant radiation * No prior radiation therapy or medical therapy directed at the tumour
Exclusion criteria
* Breastfeeding or pregnancy * Claustrophobia or inability to lie still in a supine position * Unwillingness or inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Target radiation volume | 2 years | The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan |
Secondary
| Measure | Time frame |
|---|---|
| Local control | 2 years |
| Progression-free survival | 2 years |
| Perceived usefulness by radiation oncologist | 2 years |
| Adverse event | 2 years |
| Rate of DOTATATE-scan completion | 2 years |
| Extent of post-operative disease volume compared to MRI | 2 years |
| Overall survival | 2 years |
Countries
Canada
Contacts
Primary ContactSandy Chang
Outcome results
None listed